Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • TA226
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the Liverpool Reviews and Implementation Group:

  • Bagust A, Boland A, Blundell M, et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma, October 2010

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation documents (ACD1 and ACD2). Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups, and other consultees had the opportunity to give their expert views. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, also have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Roche Products

Professional or specialist and patient or carer groups:

  • British Society for Haematology

  • Cancer Networks Pharmacists Forum

  • Cancer Research UK

  • Leukaemia CARE

  • Lymphoma Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • United Kingdom Oncology Nursing Society

Other consultees:

  • Department of Health

  • NHS Camden

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Leukaemia and Lymphoma Research

  • Medicines and Healthcare products Regulatory Agency

  • NHS Quality Improvement Scotland

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They gave their expert personal view on rituximab by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD1 and ACD2.

  • Professor Peter Johnson, Professor of Medical Oncology, nominated by National Cancer Research Institute, Royal College of Physicians, Royal College of Radiologists, Association of Cancer Physicians, Joint Collegiate Council for Oncology – clinical specialist

  • Dr Helen McCarthy, Consultant Haematologist, nominated by the Royal College of Pathologists – clinical specialist

  • Dr Robert Marcus, Consultant Haematologist, nominated by National Cancer Research Institute, Royal College of Physicians, Royal College of Radiologists, Association of Cancer Physicians, Joint Collegiate Council for Oncology – clinical specialist

  • Mandy Childs, nominated by Lymphoma CARE – patient expert

  • Elizabeth Nelson, nominated by the Lymphoma Association – patient expert

Representatives from the following manufacturer or sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products

ISBN: 978-1-4731-6677-6